Literature DB >> 7915103

Coronary artery operation supported by the Hemopump: an experimental study on pig.

U Lönn1, B Peterzén, H Granfeldt, H Casimir-Ahn.   

Abstract

Twelve pigs undergoing coronary artery bypass grafting had the Hemopump to decompress the heart and as circulatory support. The pigs also were given a short-acting beta-blocker, esmolol, to make the heart flaccid. Extracorporeal circulation was not used. During Hemopump support, a bolus dose of 0.5 to 5 mg/kg of esmolol was given before incremental titration steps from 100 to 600 micrograms.kg-1.min-1 over 15 to 20 minutes. The internal thoracic artery was sutured to the distal part of the left anterior descending artery. The Hemopump was withdrawn to the aorta after a weaning period of 20 to 30 minutes. Seven of 12 pigs went through the whole procedure and the Hemopump was weaned off without complications. Five animals died due to right ventricular failure in association with esmolol administration. There was a big interindividual difference in esmolol dose-response curves in the surviving animals. No significant differences in the hemodynamic variables were observed during the experiment. The Hemopump in combination with a short-acting beta-blocker could be an alternate way of performing coronary artery bypass grafting in selected patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915103     DOI: 10.1016/0003-4975(94)92242-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  The effects of a new ultra-short-acting beta-adrenergic blocker, ONO-1101, on cardiac function during and after cardiopulmonary bypass.

Authors:  I Ahmet; N Fukushima; Y Sawa; T Masai; K Kadoba; K Kagisaki; J C Chang; T Yamaguchi; H Matsuda
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Efficient gene transfer and durable transgene expression in grafted rabbit veins.

Authors:  Liang Du; Jingwan Zhang; Alexander W Clowes; David A Dichek
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.